Arbaprostil [15(R)-15-methyl prostaglandin E2] in a single nighttime dose of either 50 or 100 μg in acute duodenal ulcer

Euler, Arthur R.; Bailey, R.J.; Zinny, Miguel A.; Brandon, Milan L.; Rousseau, B; Ferguson, J; Wood, D.; Le, Vu

doi:10.1016/0016-5085(89)91421-2

Cited by 3 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some trials have evaluated a once daily drug administration against placebo [ 15–19]. These trials originate mainly from the United States and were published in the late 1980s and 1990s.…”

Section: Discussionmentioning

confidence: 99%

Placebo effect in the treatment of duodenal ulcer

Craen¹,

Moerman

Heisterkamp³

et al. 1999

Brit J Clinical Pharma

107

View full text Add to dashboard Cite

Aims To assess whether frequency of placebo administration is associated with duodenal ulcer healing. Methods A systematic literature review of randomized clinical trials was undertaken. 79 of 80 trials that met the inclusion criteria. The pooled 4 week placebo healing rate of all duodenal ulcer trials that employed a four times a day regimen was compared with the rate obtained from trials with a twice a day regimen. Results The pooled 4 week healing rate of the 51 trials with a four times a day regimen was 44.2% (805 of 1821 patients) compared with 36.2% (545 of 1504 patients) in the 28 trials with a twice a day regimen (difference, 8.0% [equal effects model]; 95% confidence interval, 4.6% to 11.3%). Depending on the statistical analysis, the rate difference ranged from 6.0% (multivariable random effects model) to 8.0% (equal effects model). A number of sensitivity analyses showed comparable differences between the two regimens. Most of these sensitivity analyses were not significant, probably because a number of trials were excluded resulting in a loss of power. Conclusions We found a relation between frequency of placebo administration and healing of duodenal ulcer. We realize that the comparison was based on nonrandomized data. However, we speculate that the difference between regimens was induced by the difference in frequency of placebo administration. A better knowledge of various placebo effects is required in order to make clinically relevant assessments of treatment effects derived from placebo-controlled trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Placebo effect in the treatment of duodenal ulcer

Craen¹,

Moerman

Heisterkamp³

et al. 1999

Brit J Clinical Pharma

107

View full text Add to dashboard Cite

show abstract

“…8) [85], Rioprostil [86]) and PGE 2 ( Fig. 9) (Enprostil [87], Arbaprostil [88,89]) analogs. They exert their beneficial effects through increased gastric and duodenal bicarbonate secretion, increased secretion of gastric mucus, strengthening of the gastric mucosal barrier with a reduction in H + ion back diffusion, increased maintenance of normal blood flow and decreased gastric acid secretion by decreasing cAMP levels in the parietal cells.…”

Section: Prostaglandinsmentioning

confidence: 99%

Reactive Oxygen Species-Induced Gastric Ulceration: Protection By Melatonin

Bandyopadhyay¹,

Chattopadhyay

2006

CMC

View full text Add to dashboard Cite

Gastric hyperacidity and ulceration of the stomach mucosa due to various factors are serious health problems of global concern. Although the mechanism of acid secretion from the parietal cells is now well understood, the processes involved in gastric ulceration are still not clear. Among the various causes of gastric ulceration, lesions caused by stress, alcohol consumption, Helicobacter pylori and due to use of non-steroidal anti-inflammatory drugs have been shown to be mediated largely through the generation of reactive oxygen species, especially the hydroxyl radical. A number of excellent drugs, developed over the decades, have proven useful in controlling hyperacidity and ulceration although their long-term use is reported to be associated with various side effects. Hence the investigations continue with an objective to find a compound possessing anti-secretory, anti-ulcer and antioxidant properties which will serve as a therapeutic agent to reduce gastric hyperacidity and ulcers. This article describes the role of reactive oxygen species in gastric ulceration, briefly presents a note on the currently available drugs controlling them, and focuses on the role of melatonin, a pineal secretory product, in protecting against gastric lesions. In experimental studies, melatonin has been shown to be effective in reducing mucosal breakdown and ulcer formation in a wide variety of situations. Additionally, the low toxicity of melatonin supports further investigation of this molecule as a promising gastro-protective agent. Finally, we include a commentary on how melatonin research with respect to gastric pathophysiology can move forward with a view to eventually using this indole as a therapeutic agent alone or in combination with the existing drugs to control gastric ulceration in humans in order to increase their efficacy and/or to reduce their side effects.

show abstract